
Investigating the Aggregation, Genome Release, and Self-Interactions of AAV Formulations

Lily Motabar Ph.D. Candidate, University of Delaware


June 11, 2025 CASSS Cell and Gene Therapy Symposium

Goal is understanding how formulation conditions contribute to stability of AAVs




Cartoons created in BioRender

Thermal stress studies revealed pH-dependent differences in genome release




Motabar L, et al. J Pharm Sci (2025) [In review]

Capsids aggregate reversibly at low ionic strength




Motabar L, et al. J Pharm Sci (2025) [In review]

Static light scattering experiments reveal attractive capsid self-interactions




Coarse-grained model predictions of second osmotic virial coefficient (B_{22})

1 bead per charge site and per viral protein (1bC/VP) Model



- Currently limited to two-body interactions between intact empty capsids
- Predicts repulsions at low ionic strength, and higher sensitivity to ionic strength at low pH



Motabar L, et al. J Pharm Sci (2025) [In review]

Electrostatic interactions play a significant role in stability of AAV capsids

- The insights from this work can aid in the selection of solution conditions during the development of AAV-based pharmaceuticals
- The experimental techniques and computational model contribute to the available toolbox of methods used to analyze AAV product quality and stability
- Future work: exploring other serotypes, transgenes, empty capsids, various buffer compositions and salts

